http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019144443-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f2e8d4f980eac450fe75cee98ac0758 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate | 2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6de90d737ed4a7b5503565b8d183f27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55ba9d4168f1e96534661067b2c0c771 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3c90ef004e2feb050363583e9cfc107 |
| publicationDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019144443-A1 |
| titleOfInvention | Asymmetric conjugate compounds |
| abstract | The invention relates to compound of formula (I): n A-X 1 -L-X 2 —B (I)n n and salts, solvates and tautomers thereof, which are useful as medicaments, in particular as anti-proliferative agents and for use as a drug in an antibody-drug conjugate; wherein A is a group selected from: n n n n n n n n n n X 1 and X 2 are independently selected from O, S, NR 28 , CR 28 R 29 , CR 28 R 29 O, C(═O), C(═O)NR 28 , NR 28 C(═O), C(O)—R A —C(O)—NH, C(O)—R A —NH—C(O), C(O)—NH—R A —C(O), NH—C(O)—R A —C(O), NH—C(O)—R A —C(O)—NH, NH—C(O)—R A —NH—C(O), C(O)—NH—R A —NH—C(O), C(O)—NH—R A —C(O)—NH, O—C(O) and C(O)—O or is absent;n nL is selected from an amino acid, a peptide chain having from 2 to 12 amino acids, a paraformaldehyde chain —(OCH 2 ) 1-24 —, a polyethylene glycol chain —(OCH 2 CH 2 ) 1-12 — and —(CH 2 ) m —Y 6 —(CH 2 ) n — wherein Y 6 is selected from —(CH 2 ) z — and a group (L1) a group (L1) that is selected from arylene, monocyclic heteroarylene, monocyclic cycloalkylene, monocyclic cycloalkenylene and monocyclic heterocyclylene groups optionally substituted with up to three optional substituent groups; andn nB is a polycyclic group selected from: |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11750794-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766296-B2 |
| priorityDate | 2016-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2073.